Apathy in Parkinson Disease TMS Study (PDTMSAPATHY)
Parkinson Disease
About this trial
This is an interventional basic science trial for Parkinson Disease focused on measuring Apathy, Motivation
Eligibility Criteria
Inclusion Criteria: Diagnosis of idiopathic Parkinson Disease. At least 5 years of symptoms. On dopaminergic medication for Parkinson Disease. Stable on dopaminergic medication and other medications which may influence apathy (such as selective serotonin re-uptake inhibitors, stimulant medications) for at least 4 weeks prior to first study visit and remain stable throughout the study period. Hospital's study-specific informed consent must be obtained. Must have capacity to provide informed consent in English. For female participants, confirmation that they have not had a menstrual period in over 12 months, or that they will use an effective form of contraception during the study. Exclusion Criteria: Inability to provide informed consent. Inability to perform effort task (determined during the titration session). Presence of dementia (Montreal Cognitive Assessment (MoCA) score < 21). History of epilepsy or brain surgery. Severe tremor or dyskinesia that would interfere with EEG (determined by the PI). Patients with clinically significant medical or neurological conditions which may be an alternative cause of parkinsonism such as repeated brain injury, anti-dopaminergic medications, anoxic brain injury, or significant basal ganglia strokes. Presence of other known central nervous system disease that may interfere with performance or interpretation of EEG or TMS. Presence of any implanted metal devices including, but not limited to, pacemakers, deep brain stimulators, vagal nerve stimulators, bladder stimulators, or cochlear implants. Presence of medical contraindications to TMS such as implanted stimulators, history of mania or bipolar disorder, history of epilepsy.
Sites / Locations
- Carolina Center for Neurostimulation at UNC-Chapel Hill
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Medial Prefrontal Cortex - Control Site
Control Site - Medial Prefrontal Cortex
Participants first undergo transcranial magnetic stimulation to the medial prefrontal cortex. After a 3-week washout period, participants then undergo transcranial magnetic stimulation to the control site.
Participants first undergo transcranial magnetic stimulation to the control site. After a 3-week washout period, participants then undergo transcranial magnetic stimulation to the medial prefrontal cortex.